Uptravi
Chemical Name | selexipag |
Dosage Form | Tablet (oral; 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1000 mcg, 1200 mcg, 1400 mcg, 1600 mcg) |
Drug Class | Receptor agonists |
System | Cardiovascular |
Company | Actelion Pharms Ltd |
Approval Year | 2015 |
Indication
- For the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.